# Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT02344017** · PHASE1,PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ODM-204
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02344017
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344017, "Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02344017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*